Theralase Technologies Inc (TLTFF)

[123414]

It will be substantially increased in value because the science is solid and is being validated as we wait.

The rat model went 20 months without a tumor growing back even after being reinfected with cancer cells.

That Sir, is the real deal. I expect more news to be released after the three patients at the .35 dosage have received the 6 month checkup.


This is a phase Ib, open-label, single-arm, single-center study conducted in Canada. Subjects with NMIBC (Ta, T1, and/or Tis) who are not candidates for or have refused radical cystectomy will be eligible for participation in the study. BCG intolerance or refractory disease are defined as inability to tolerate or failure to achieve a tumour-free state after at least one induction (a minimum of 5 instillations) followed by either a second induction (a minimum of 5 instillations) or at least 2 maintenance instillations. Subjects experiencing disease relapse within 12 months or less after finishing the second course of BCG therapy are also considered refractory. The study will consist of 2 phases. In the first phase, 3 subjects will receive PDT (TLC-3200 System) employing 0.35 mg/cm^2 (maximum recommended starting dose) TLD1433.

Other Outcome Measures:
Efficacy: Recurrence is defined as the interval from Day 0 to documented recurrence [ Time Frame: The overall efficacy will be evaluated during the course of the study (at 3 and 6 months) ]

https://clinicaltrials.gov/ct2/show/NCT03053635?term=1433&cond=bladder+cancer&rank=1


They knocked it out of the park for the 3 month checkup. AKA NO REOCCURANCE AKA RESPONSE
http://theralase.com/pressrelease/theralase-achieves-exploratory-endpoint-of-efficacy-for-anti-cancer-technology/

Fast link for reading up on the real deal that's about to be a real big deal...
http://theralase.com/press-releases/

Bladder cancer market alone was worth 3.9 billion in 2016.